Verve Medical key facts
as of Oct 2026- Developer of renal denervation devices intended to reduce hypertension.
- Verve Medical is valued at approximately $64.0M as of Oct 2026, set at its later-stage round, Aug 2020; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $11.2M across 2 recorded rounds; the latest was Seed Round ($470K) in Oct 2016.
- Notable investors include Flinn Foundation, BioAccel, HM Venture Partners, LongRiver Investments.
- Verve Medical has filed 3 Form Ds with the SEC since 2015, most recently Jan 2017 ($470K sold to 5 investors).
- Status: Privately Held (backing).
Valued at $64.0M at its later-stage round, Aug 2020. Nothing has traded since.
- ·Watch Verve Medical: the Monday email on marks, rounds and moves
Verve Medical funding rounds
2 roundsWho backs Verve Medical
4Verve Medical valuation
Verve Medical was valued at $64 million at its later-stage round in Aug 2020. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Verve Medical raised?
Verve Medical has raised $11.2 million in total; 2 of its rounds are on record. The largest on record was a $470,000 seed round in Oct 2016.
Verve Medical has filed 3 Form Ds with the SEC since 2015, most recently in Jan 2017 ($470,000 sold to 5 investors).
Verve Medical investors
4 investors are on record for Verve Medical, including Flinn Foundation, BioAccel, HM Venture Partners and LongRiver Investments. The seed round in Oct 2016 drew 5 investors.
About Verve Medical
Developer of renal denervation devices intended to reduce hypertension. The company's devices reduce systolic blood pressure for treating hypertension by reducing the sympathetic nervous system drive through renal denervation, enabling patients to reduce the risk related to stroke and heart disease.
- Sector
- Healthcare
- HQ
- Phoenix, AZ, United States
- Founded
- 2010
- Employees
- 8
- Website
- verve-medical.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.